Fırat Ortaç

Ankara University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Salih Taşkın

Ankara University

105

Mete Güngör

Acıbadem University

Duygu Altın

Ankara University

Ali Ayhan

Başkent University

MŞ

Muzaffer Şancı

Izmir University

Murat Sönmezer

Ankara University

Bulut Varlı

Ankara University

ÇT

Çağatay Taşkıran

Koç University

Tayfun Toptaş

Sağlık Bilimleri Üniversitesi

Fuat Demirkıran

Istanbul University

Cooperative Institutions

Sağlık Bilimleri Üniversitesi

138

Ankara University

129

Gynecologic Oncology Group

Zübeyde Hanim Maternity Hospital

University of Health Science

University of Health Sciences

Hacettepe University

Ministry of Health

Etlik Zübeyde Hanım Kadın Hastalıkları Eğitim ve Araştırma Hastanesi

Başkent University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study

Journal of Gynecologic Oncology (2023)

Okan Oktar Vakkaş Korkmaz Abdurrahman Alp Tokalıoğlu Çağatayhan Öztürk Özgür Erdoğan

To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT).

10.3802/jgo.2024.35.e39

Cite

Citations (0)

Pembrolizumab Or Placebo Plus Adjuvant Chemotherapy With Or Without Radiotherapy In Patients With Newly Diagnosed, High-Risk Endometrial Cancer: Exploratory Analysis Of Disease-Specific Survival From The Phase 3 ENGOT-En11/GOG-3053/KEYNOTE-B21 Study

International Journal of Gynecological Cancer (2025)

Michael J. Halaška Toon Van Gorp Weiguo Lv Floor J. Backes Fırat Ortaç

10.1016/j.ijgc.2025.101700

Cite

Citations (0)

Features of ovarian Brenner tumors: Experience of a single tertiary center

Journal of Turkish Society of Obstetric and Gynecology (2017)

Batuhan Turgay Kazibe Koyuncu Salih Taşkın Fırat Ortaç

ÖzAmaç: Brenner tümörleri overin nadir neoplazmlarındandır

Serous Cystadenoma

Mucinous cystadenoma

Ovarian tumor

10.4274/tjod.98216

Cite

Citations (16)

PharmaNews

Oncology Research and Treatment (2017)

Kemal Güngördük İsa Aykut Özdemir Tayfun Güngör Elçin Telli Salih Taşkın

10.1159/000470891

Cite

Citations (0)

Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study

Cancer Research and Treatment (2014)

Kemal Güngördük İbrahim Egemen Ertaş Aykut Özdemir Emrah Akkaya Elçin Telli

The purpose of this study is to evaluate the prognostic role of preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) and the need for para-aortic lymphadectomy in patients with primary fallopian tube carcinoma (PFTC).Ninety-one patients with a diagnosis of PFTC were identified through the gynecologic oncology service database of six academic centers. Clinicopathological, surgical, and complete blood count data were collected.In univariate analysis, advanced stage, suboptimal surgery, and NLR > 2.7 were significant prognostic factors for progression-free survival, whereas in multivariate analysis, only advanced stage and suboptimal surgery were significant. In addition, in univariate analysis, cancer antigen 125 ≥ 35 U/mL, ascites, advanced stage, suboptimal surgery, NLR > 2.7, PLR > 233.3, platelet count ≥ 400,000 cells/mm(3), staging type, and histological subtype were significant prognostic factors for overall survival (OS); however, in multivariate analysis, only advanced stage, suboptimal surgery, NLR > 2.7, and staging type were significant. Inclusion of pelvic and para-aortic lymphadenectomy in surgery showed significant association with longer OS, with a mean and median OS of 42.0 months and 35.5 months (range, 22 to 78 months), respectively, vs. 33.5 months and 27.5 months (range, 14 to 76 months), respectively, for patients who underwent surgery without para-aortic lymphadenectomy (hazard ratio, 3.1; 95% confidence interval, 1.4 to 5.7; p=0.002).NLR (in both univariate and multivariate analysis) and PLR (only in univariate analysis) were prognostic factors in PFTC. NLR and PLR are inexpensive and easy tests to perform. In addition, patients with PFTC who underwent bilateral pelvic and para-aortic lymphadenectomy had longer OS.

Univariate analysis

Lymphadenectomy

Gynecologic oncology

10.4143/crt.2014.058

Cite

Citations (22)

EP544 Saten III - splitting adjuvant treatment into subgroups of stage III endometrioid endometrial cancers: an international, multicenter study

İlker Kahramanoğlu MM Meydanlı S Taranenka Ali Ayhan Mehmet Coşkun Salman

Introduction/Background

The primary aim was to determine whether different adjuvant treatment modalities (CT, RT, and CRT) improve survival outcomes in stage III endometrioid EC patients based on the specific sub-stage of the disease. The secondary aim was to assess the prognostic factors in stage III endometrioid EC.

Methodology

SATEN III was a retrospective study involving 13 centers from 10 countries. Patients who had been operated on between 1998 and 2018 and diagnosed with stage III endometrioid EC were analyzed.

Results

A total of 990 women overall were identified; 317 with stage IIIA, 18 with stage IIIB, and 655 with stage IIIC diseases. The median follow-up was 42 months. The 5-year DFS of patients with stage III EC by adjuvant treatment modality was 68.5% for radiotherapy (RT), 54.6% for chemotherapy (CT), and 69.4% for chemoradiation (CRT) (p=0.11). The 5-year OS for those patients was 75.6% for RT, 75% for CT, and 80.7% for CRT (p=0.48). Negative peritoneal cytology (Hazard ratio [HR]: 0.45, 95% confidence interval [CI]: 0.23–0.86; p=0.02) and performance of lymphadenectomy (HR: 0.33, 95% CI: 0.16–0.77, p=0.001) were independent predictors for improved OS for stage IIIA EC. Independent prognostic factors for better OS for stage IIIC disease were age <60 (HR: 0.50, 95%CI: 0.36–0.69, p<0.001), grade 1 or 2 disease (HR: 0.59, 95% CI: 0.37–0.94, p=0.014; and HR: 0.65, 95% CI: 0.46–0.91, p=0.014, respectively), absence of cervical stromal involvement (HR: 063, 95% CI: 0.46–0.86, p=0.004) and performance of para-aortic lymphadenectomy (HR: 0.52, 95% CI: 0.35–0.72, p<0.001).

Conclusion

Although not statistically significant, CRT seemed to be a better adjuvant treatment option for stage IIIA endometrioid EC. However, we were not able to show the superiority of adjuvant CRT in stage IIIC endometrioid EC.Systematic lymphadenectomy seemed to improve survival outcomes in stage III endometrioid EC.

Disclosure

Nothing to disclose.

Lymphadenectomy

10.1136/ijgc-2019-esgo.601

Cite

Citations (0)

A Turkish Gynecologic Oncology Group study of fertility‐sparing treatment for early‐stage endometrial cancer

International Journal of Gynecology & Obstetrics (2012)

Polat Dursun Serkan Erkanlı Ahmet Barış Güzel Murat Gültekin Nefise Çağla Tarhan

Gynecologic oncology

10.1016/j.ijgo.2012.06.010

Cite

Citations (33)

Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study

Oncology Research and Treatment (2017)

Kemal Güngördük Aykut Özdemir İlker Selçuk Elçin Telli Öztürk Şahin

Introduction: We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC). Methods: 22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data. Results: The mean age of HG-sPFTC patients was 59.4 ± 6.2 years, and that of HG-sEOC patients 55.2 ± 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75). Conclusion: The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar.

Fallopian tube

Fallopian tube cancer

10.1159/000458440

Cite

Citations (2)

Surgical conservation of both ovaries in an adolescent with uterine müllerian adenosarcoma: A case report

Journal of Minimally Invasive Gynecology (2007)

Batuhan Özmen Nüket Üzüm Cihat Ünlü Fırat Ortaç Ömür Ataoğlu

Anti-Müllerian hormone

Adjuvant Chemotherapy

Ovarian Reserve

10.1016/j.jmig.2007.01.006